Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms MEKRT
- 22 Feb 2018 Status changed from recruiting to completed.
- 08 Feb 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 08 Apr 2013 Planned end date changed from 1 Feb 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.